A Phase I/II Trial of ZD1839 (Iressa) and Rapamycin (Rapamune) in Patients With Advanced Non Small Cell Lung Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2012
At a glance
- Drugs Gefitinib (Primary) ; Sirolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Dec 2008 Status changed from recruiting to withdrawn prior to recruitment.
- 05 Aug 2005 New trial record.